BRPI0806578A8 - Promotores de lactococcus e usos dos mesmos - Google Patents

Promotores de lactococcus e usos dos mesmos

Info

Publication number
BRPI0806578A8
BRPI0806578A8 BRPI0806578A BRPI0806578A BRPI0806578A8 BR PI0806578 A8 BRPI0806578 A8 BR PI0806578A8 BR PI0806578 A BRPI0806578 A BR PI0806578A BR PI0806578 A BRPI0806578 A BR PI0806578A BR PI0806578 A8 BRPI0806578 A8 BR PI0806578A8
Authority
BR
Brazil
Prior art keywords
nucleic acids
lactococcus
promoters
proteins
relates
Prior art date
Application number
BRPI0806578A
Other languages
English (en)
Inventor
Steidler Lothar
Vandenbroucke Klaas
Neirynck Sabine
Original Assignee
Actogenix Nv
Intrexon Actobiotics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actogenix Nv, Intrexon Actobiotics N V filed Critical Actogenix Nv
Publication of BRPI0806578A2 publication Critical patent/BRPI0806578A2/pt
Publication of BRPI0806578A8 publication Critical patent/BRPI0806578A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROMOTORES DE LACTOCOCCUS E USOS DOS MESMOS. A presente invenção está no campo de biologia molecular e refere-se à engenharia recombinante e expressão de proteína. Mais em particular, a invenção refere-se a ácidos nucleicos para expressão recombinante de proteínas compreendendo sequências derivadas de Lactococcus e úteis como promotores. A invenção refere-se ainda a vetores compreendendo os ditos ácidos nucleicos e células hospedeiro transformadas com eles. A invenção também compreende o uso de células hospedeiro compreendendo os ditos ácidos nucleicos ou vetores para expressão de proteínas heterólogas ou homólogas; e também para aplicação, especialmente aplicação terapêutica, das ditas proteínas a indivíduos.
BRPI0806578A 2007-01-12 2008-01-14 Promotores de lactococcus e usos dos mesmos BRPI0806578A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07447001 2007-01-12
EP07447001.4 2007-01-12
EP07120653.6 2007-11-14
EP07120653 2007-11-14
PCT/EP2008/050352 WO2008084115A2 (en) 2007-01-12 2008-01-14 Lactococcus promoters and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0806578A2 BRPI0806578A2 (pt) 2014-05-06
BRPI0806578A8 true BRPI0806578A8 (pt) 2016-11-16

Family

ID=39609090

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806578A BRPI0806578A8 (pt) 2007-01-12 2008-01-14 Promotores de lactococcus e usos dos mesmos

Country Status (11)

Country Link
US (1) US8759088B2 (pt)
EP (2) EP3124614B1 (pt)
JP (1) JP5584470B2 (pt)
KR (1) KR101557509B1 (pt)
CN (1) CN101605900B (pt)
AU (1) AU2008204442B2 (pt)
BR (1) BRPI0806578A8 (pt)
CA (1) CA2675115C (pt)
ES (1) ES2595729T3 (pt)
RU (1) RU2495129C2 (pt)
WO (1) WO2008084115A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010034844A1 (en) * 2008-09-29 2010-04-01 Actogenix N.V. Reduced colonization of microbes at the mucosa
FR2947840B1 (fr) * 2009-07-09 2011-09-02 G T P Technology S A Sequence promotrice pour l'expression de proteines recombinantes chez lactococcus lactis
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
EP2483409B1 (en) 2009-09-29 2017-03-22 Intrexon Actobiotics NV LACTOBACILLUS glyceraldehyde-3-phosphate dehydrogenase PROMOTERS AND USES THEREOF
JP6033780B2 (ja) * 2010-10-15 2016-11-30 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 内分泌障害、胃腸障害または自己免疫障害を処置するための組成物および方法
RU2766157C2 (ru) 2011-06-01 2022-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
DK2758512T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
CA2848471C (en) 2011-09-23 2021-11-16 Actogenix Nv Modified gram positive bacteria and uses thereof
TW201632625A (zh) 2011-11-28 2016-09-16 第一三共股份有限公司 源自人類基因的啟動子
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
FR2990699B1 (fr) 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
US9452205B2 (en) 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
US9534041B2 (en) 2013-02-12 2017-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize a norovirus
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
EP3583950A1 (en) 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
WO2015023268A1 (en) * 2013-08-13 2015-02-19 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
US10383921B2 (en) 2013-08-13 2019-08-20 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
WO2015022798A1 (ja) * 2013-08-13 2015-02-19 学校法人北里研究所 新規テルペノイド化合物およびその製造方法
WO2016090170A1 (en) 2014-12-05 2016-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A potent anti-influenza a neuraminidase subtype n1 antibody
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
WO2016164422A2 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
GB2545395A (en) * 2015-11-27 2017-06-21 The Inst Of Food Res Engineered lactococcus lactis producing biologically active GLP-1
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
EP3445857B1 (en) * 2016-04-20 2023-07-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
AU2017319707B2 (en) 2016-09-02 2023-11-09 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
EP3512872A1 (en) 2016-09-13 2019-07-24 Intrexon Actobiotics NV Mucoadhesive microorganism
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
KR101992345B1 (ko) * 2017-12-29 2019-09-27 (주)메디톡스 프로모터 폴리뉴클레오티드, 신호 폴리펩티드 및 그의 용도
KR101915949B1 (ko) * 2018-01-09 2018-11-07 주식회사 쎌바이오텍 유전자 발현 카세트 및 그를 포함하는 발현벡터
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
AU2020356592A1 (en) 2019-09-27 2022-04-07 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
EP4417684A4 (en) 2021-10-11 2026-03-25 Ajinomoto Kk BACTERIA MODIFIED TO EXPRESS A PROTEIN TAT HETEROLOGUE
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
CN118834876B (zh) * 2024-08-21 2025-03-21 迪辅乐生物(上海)有限公司 一种乳酸菌组成型启动子、重组载体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD297839A5 (de) 1988-08-23 1992-01-23 Dana Farber Cancer Institute,Us Alpha-untereinheit des lfa-l-leukozytadhaesionsrezeptors
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
ES2176188T3 (es) 1991-02-14 2002-12-01 Gen Hospital Corp Proteinas intestinales trefoil.
US6221840B1 (en) 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6190658B1 (en) * 1998-05-08 2001-02-20 Webb-Waring Institute For Biomedical Research Genetically modified manganese superoxide dismutase for treating oxidative damage
ATE259829T1 (de) 1998-10-20 2004-03-15 Vlaams Interuniv Inst Biotech Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
PT1739178E (pt) * 1999-07-05 2010-11-17 Actogenix Nv Libertação de péptidos trifólios
CN1281894A (zh) * 1999-07-23 2001-01-31 中国人民解放军第二军医大学南京军医学院 转人内皮抑素(Endostatin)基因乳酸菌的方法、产品及其应用
FR2809404B1 (fr) * 2000-05-29 2002-08-30 Rhodia Chimie Sa Bacteriocine anti-listeria
PT1356073E (pt) * 2000-10-20 2010-02-15 Bioneer As Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
AU2002314040B2 (en) * 2001-05-03 2007-06-28 Intrexon Actobiotics Nv Self-containing lactococcus strain
EP1529114A1 (en) * 2002-08-09 2005-05-11 Chr. Hansen A/S Process for preparing peptides with anti-hypertensive properties
ATE495246T1 (de) * 2004-11-24 2011-01-15 Anaeropharma Science Inc Neuartiger shuttle-vektor
KR100620092B1 (ko) 2004-12-16 2006-09-08 씨제이 주식회사 코리네박테리움 속 세포로부터 유래된 신규한 프로모터서열, 그를 포함하는 발현 카세트 및 벡터, 상기 벡터를포함하는 숙주 세포 및 그를 이용하여 유전자를 발현하는방법
DE102004061846A1 (de) 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
US7495092B2 (en) * 2005-01-14 2009-02-24 North Carolina State University Compositions comprising promoter sequences and methods of use

Also Published As

Publication number Publication date
EP2115146A2 (en) 2009-11-11
JP5584470B2 (ja) 2014-09-03
KR20090112650A (ko) 2009-10-28
CN101605900B (zh) 2014-04-23
EP3124614B1 (en) 2022-06-08
AU2008204442A1 (en) 2008-07-17
RU2495129C2 (ru) 2013-10-10
EP2115146B1 (en) 2016-07-06
RU2009130728A (ru) 2011-02-20
JP2010515445A (ja) 2010-05-13
CA2675115C (en) 2014-12-09
CN101605900A (zh) 2009-12-16
US8759088B2 (en) 2014-06-24
EP3124614A3 (en) 2017-04-05
US20100080774A1 (en) 2010-04-01
ES2595729T3 (es) 2017-01-03
WO2008084115A3 (en) 2009-04-09
AU2008204442B2 (en) 2013-03-14
EP3124614A2 (en) 2017-02-01
BRPI0806578A2 (pt) 2014-05-06
WO2008084115A2 (en) 2008-07-17
KR101557509B1 (ko) 2015-10-06
CA2675115A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008084115A3 (en) Lactococcus promoters and uses thereof
Morris et al. The host response to naturally-derived extracellular matrix biomaterials
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
MX2022015080A (es) Variantes de hsd17b13 y usos de las mismas.
BR112012019881A2 (pt) proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
EP2563911A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF ALANYL-TRNA SYNTHETASES
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
MX2016008551A (es) Moleculas artificiales de acido nucleico.
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
MX339126B (es) Composiciones de dominio de fibronectina estabilizadas, metodos y usos.
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
ATE537188T1 (de) Serumalbuminbindende proteine
NZ609903A (en) Expression vector for high level expression of recombinant proteins
BR112016023304A2 (pt) célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INTREXON ACTOBIOTICS N.V. (BE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: INTREXON ACTOBIOTICS N.V. (BE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.